

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Washington D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 29 July 1996 (29.07.96)	
International application No. PCT/GB95/02893	Applicant's or agent's file reference 27.61695/002.hd
International filing date (day/month/year) 12 December 1995 (12.12.95)	Priority date (day/month/year) 12 December 1994 (12.12.94)
Applicant DEGGERDAL, Arne, Helge et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

11 July 1996 (11.07.96)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Catherine Massetti
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 730.91.11

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

COMMUNICATION OF
INTERNATIONAL APPLICATIONS

(PCT Article 20)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

Date of mailing:

12 September 1996 (12.09.96)

in its capacity as designated Office

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:

PCT/GB95/02893

International publication no.:

WO96/18731

**CORRECTED VERSION
VERSION CORRIGEE**The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra
Telephone No.: (41-22) 730.91.11

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

DZIEGLEWSKA, Hanna, Eva
Frank B. Dehn & Co.
179 Queen Victoria Street
London EC4V 4 EL
ROYAUME-UNI

Date of mailing
(day/month/year) 20 June 1996 (20.06.96)

Applicant's or agent's file reference
27.61695-002.hd

IMPORTANT NOTIFICATION

International application No.
PCT/GB95/02893

International filing date
(day/month/year) 12 December 1995 (12.12.95)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address

DZIEGLEWSKA, Hanna, Eva
Frank B. Dehn & Co.
Imperial House
15-19 Kingsway
London WC2B 6UZ
United Kingdom

State of Nationality

State of Residence

Telephone No.

171-836-6193

Facsimile No.

171-240-0776

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

DZIEGLEWSKA, Hanna, Eva
Frank B. Dehn & Co.
179 Queen Victoria Street
London EC4V 4 EL
United Kingdom

State of Nationality

State of Residence

Telephone No.

171-206-0600

Facsimile No.

171-206-0700

Teleprinter No.

3. Further observations, if necessary: The above change is valid only as from 24 June 1996 (24.06.96).

4. A copy of this notification has been sent to:

☒ the receiving Office ☒ the designated Offices concerned
☐ the International Searching Authority ☐ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

M. Abidine

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 730.91.11

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

DZIEGLEWSKA, Hanna, Eva
Frank B. Dehn & Co.
179 Queen Victoria Street
London EC4V 4 EL
ROYAUME-UNIDate of mailing (day/month/year)
18 June 1997 (18.06.97)Applicant's or agent's file reference
27.61695/002.hd

IMPORTANT NOTIFICATION

International application No.
PCT/GB95/02893International filing date (day/month/year)
12 December 1995 (12.12.95)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

DZIEGLEWSKA, Hanna, Eva
Frank B. Dehn & Co.
Imperial House
15-19 Kingsway
London WC2B 6UZ
United-KingdomState of Nationality
GBState of Residence
GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

State of Nationality

State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

The name of the applicant listed in Box 1 should now be deleted from record.

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

R. Raissi

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 95/02893

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 25912 (MEDICAL RESEARCH COUNCIL) 23 December 1993 *see the whole patent*	1-18
X	JOURNAL OF APPLIED BACTERIOLOGY, vol. 74, 1993, pages 78-85, XP002007385 K. SMALLA ET AL.: "Rapid DNA extraction protocol from soil for polymerase chain reaction mediated amplification" *see the whole article*	1-18

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

3 July 1996

Date of mailing of the international search report

02.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Marie, A

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 95/02893

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 60, no. 5, 1994, pages 1572-1580, XP002007386 M.I. MORE ET AL.: "Quantitative cell lysis of indigenous microorganisms and rapid extraction of microbial DNA from sediment" *see the whole article* ---	1-18
X	EMBO JOURNAL, vol. 4, no. 4, 1985, pages 913-918, XP002007387 D.A. JACKSON ET AL.: "A general method for preparing chromatin containing intact DNA" *see the whole article* ---	1-18
X	EMBO JOURNAL, vol. 3, no. 8, 1984, pages 1837-1842, XP002007388 P.R. COOK : "A general method for preparing intact nuclear DNA" *see the whole article* ---	1-18
X	EXPERIMENTAL CELL RESEARCH, vol. 190, 1990, pages 294-296, XP002007389 G. KONAT ET AL.: "Rapid isolation of genomin DNA from animal Tissues" *see the whole article* ---	1-18
X	ANALYTICAL BIOCHEMISTRY, vol. 164, 1987, pages 207-213, XP002007390 P.M. GLEE ET AL.: "Methods for DNA extraction from Candida albicans" *see the whole article* -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/GB 95/02893

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9325912	23-12-93	AU-B- 4343993	04-01-94
		AU-B- 4344093	04-01-94
		WO-A- 9325709	23-12-93

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/10	A3	(11) International Publication Number: WO 96/18731 (43) International Publication Date: 20 June 1996 (20.06.96)
(21) International Application Number: PCT/GB95/02893 (22) International Filing Date: 12 December 1995 (12.12.95) (30) Priority Data: 9425138.6 12 December 1994 (12.12.94) GB (71) Applicant (for all designated States except US): DYNAL A/S [NO/NO]; Skøyen, P.O. Box 158, N-0212 Oslo 2 (NO). (71) Applicant (for GB only): DZIEGLEWSKA, Hanna, Eva [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DEGERDAL, Arne, Helge [NO/NO]; Engelsrudlia 57, N-1317 Asker (NO). LARSEN, Frank [NO/NO]; Gaustadveien 93, N-0372 Oslo (NO). (74) Agents: DZIEGLEWSKA, Hanna, Eva et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the international search report: 12 September 1996 (12.09.96)
(54) Title: ISOLATION OF NUCLEIC ACID (57) Abstract <p>The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be coupled with a further step to isolate RNA from the same sample.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 44 -

Claims

1. A method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support in the presence of said detergent and absence of chaotropic agent, and separating said support with bound nucleic acid from the sample.

2. A method as claimed in claim 1, wherein the nucleic acid is RNA.

3. A method as claimed in claim 1, wherein the nucleic acid is DNA.

4. A method as claimed in claim 1, further comprising an additional step to isolate RNA from the sample.

5. A method as claimed in any one of claims 1 to 4, further comprising one or more additional steps to disrupt structural components in the sample or to achieve lysis of cells in the sample.

6. A method as claimed in any one of claims 1 to 5, wherein the detergent is anionic.

7. A method as claimed in claim 6, wherein the detergent is sodium dodecyl sulphate, or another alkali metal alkylsulphate salt, or sarkosyl.

8. A method as claimed in any one of claims 1 to 7, wherein the concentration of detergent is 0.2 to 30% (w/v).

9. A method as claimed in any one of claims 1 to 8, wherein the detergent is contained in a composition additionally comprising one or more monovalent cations, chelating agents or reducing agents.

AMENDED SHEET

THIS PAGE BLANK (USPTO)

- 45 -

10. A method as claimed in any one of claims 1 to 9,
wherein the detergent is used in alkaline solution.
11. A method as claimed in any one of claims 1 to 10,
5 wherein the solid support is particulate.
12. A method as claimed in claim 11, wherein the solid
support comprises magnetic beads.
- 10 13. A method as claimed in any one of claims 1 to 12,
wherein the solid support has a hydrophobic surface.
14. A method as claimed in any one of claims 1 to 13,
wherein the nucleic acid is eluted from the support,
15 following separation from the sample.
15. A method as claimed in claim 14, wherein the
nucleic acid is eluted by heating.
- 20 16. A kit for isolating nucleic acid from a sample,
comprising a solid support and one or more detergents as
defined in any one of claims 1 to 13.
17. A kit as claimed in claim 16, further comprising
25 one or more buffers, salts, lysis agents, chelating
agents and/or reducing agents.
18. A kit as claimed in claim 16 or claim 17, further
comprising means for isolating RNA.

30

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/10	A2	(11) International Publication Number: WO 96/18731 (43) International Publication Date: 20 June 1996 (20.06.96)
(21) International Application Number: PCT/GB95/02893 (22) International Filing Date: 12 December 1995 (12.12.95) (30) Priority Data: 9425138.6 12 December 1994 (12.12.94) GB (71) Applicant (for all designated States except US): DYNAL A/S [NO/NO]; Skøyen, P.O. Box 158, N-0212 Oslo 2 (NO). (71) Applicant (for GB only): DZIEGLEWSKA, Hanna, Eva [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DEGERDAL, Arne, Helge [NO/NO]; Engelsrudlia 57, N-1317 Asker (NO). LARSEN, Frank [NO/NO]; Gaustadveien 93, N-0372 Oslo (NO). (74) Agents: DZIEGLEWSKA, Hanna, Eva et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ISOLATION OF NUCLEIC ACID (57) Abstract The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be coupled with a further step to isolate RNA from the same sample.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Isolation of Nucleic Acid

The present invention relates to the isolation of nucleic acid, and especially to the isolation of DNA or RNA from cells.

The isolation of DNA or RNA is an important step in many biochemical and diagnostic procedures. For example, the separation of nucleic acids from the complex mixtures in which they are often found is frequently necessary before other studies and procedures eg. detection, cloning, sequencing, amplification, hybridisation, cDNA synthesis etc. can be undertaken; the presence of large amounts of cellular or other contaminating material eg. proteins or carbohydrates, in such complex mixtures often impedes many of the reactions and techniques used in molecular biology. In addition, DNA may contaminate RNA preparations and vice versa. Thus, methods for the isolation of nucleic acids from complex mixtures such as cells, tissues etc. are demanded, not only from the preparative point of view, but also in the many methods in use today which rely on the identification of DNA or RNA eg. diagnosis of microbial infections, forensic science, tissue and blood typing, detection of genetic variations etc.

In RNA identifications it is important for a conclusive diagnosis to be certain that the detected sequence is derived from an RNA molecule and not from genomic DNA contamination in the sample. For this reason, methods for the separation of RNA from DNA are important. Also, for RNA isolation rapid methods are required since RNA molecules usually are very unstable and rapidly degraded by RNases present in cells and body fluids. The quality of the RNA is probably the most important factor in determining the quality of the final results in protocols utilising mRNA, especially for cDNA synthesis. It is important to avoid DNA contamination

of RNA preparations for a number of reasons. Firstly, DNA increases viscosity making sample handling difficult leading to poor RNA yield and also RNA of poor quality with the likelihood of DNA contamination. Also, DNA contamination may trap RNase enzymes and make downstream applications such as RT-PCR worthless.

A range of methods are known for the isolation of nucleic acids, but generally speaking, these rely on a complex series of extraction and washing steps and are time consuming and laborious to perform. Moreover, the use of materials such as alcohols and other organic solvents, chaotropes and proteinases is often involved, which is disadvantageous since such materials tend to interfere with many enzymic reactions and other downstream processing applications.

Thus, classical methods for the isolation of nucleic acids from complex starting materials such as blood or blood products or tissues involves lysis of the biological material by a detergent or chaotrope, possibly in the presence of protein degrading enzymes, followed by several extractions with organic solvents eg. phenol and/or chloroform, ethanol precipitation, centrifugations and dialysis of the nucleic acids. The purification of RNA from DNA may involve a selective precipitation with LiCl or a selective isolation with acidic guanidinium thiocyanate combined with phenol extractions and ethanol precipitation. Not only are such methods cumbersome and time consuming to perform, but the relatively large number of steps required increases the risk of degradation, sample loss or cross-contamination of samples where several samples are simultaneously processed. In the case of RNA isolation, the risk of DNA contamination is relatively high.

In purification of RNA, it is commonly desired to specifically isolate mRNA. Most mRNA purification strategies involve isolation of total RNA and fractionation of the isolated RNA. Preparation of high-

- 3 -

quality mRNA is an important step in the analysis of gene structure and gene regulation.

Most eukaryotic mRNAs have a poly(A) tail, typically about 50 to 300 nucleotides long. Such mRNA is referred to as polyadenylated or poly(A)⁺ mRNA. In separating this polyadenylated RNA from the non-adenylated RNA which accounts for 95% or more of a cell's total RNA, advantage is taken of this poly(A) tail and some type of affinity separation directed toward the poly(A) tail is performed. The conventional technology has involved purification of total RNA as a first step and selection of poly(A)⁺ RNA by affinity chromatography using oligo(dT)-cellulose as the second step. This strategy, is rather time-consuming and labour-intensive. An alternative strategy for mRNA purification is to use oligo(dT) linked to solid supports such as microplates, latex, agarose or magnetic beads.

Over the past four years it has become increasingly popular to employ a magnetic bead assisted strategy for poly(A)⁺ RNA selection since such beads have proven to be favourable in mRNA manipulations. In many approaches, the yield and the quality of the products depends on how rapidly the mRNA can be purified from nucleases and other contaminants. By using the magnetic bead separation technology, pure, intact poly(A)⁺ RNA can be obtained rapidly either from total RNA preparations or more importantly, directly from crude lysates of solid tissues, cell or body fluids. The entire procedure can be carried out in a microfuge tube without phenol extractions or ethanol precipitations.

One approach common in RNA purification, which may be used in conjunction with the solid phase approach is to carry out the lysis of the biological material and the subsequent hybridisation to oligo dT in LiCl and LiDS/SDS buffers, thereby avoiding extra steps such as phenol extraction or proteinase-K digestion. The whole direct mRNA isolation takes approximately 15 minutes and

- 4 -

since the mRNA is stable for more than 30 minutes in the lysis buffer, this ensures the high quality of the mRNA purified. However, a disadvantage of this method is that mRNA per weight unit of tissue is affected by the amount of tissue used and above a critical threshold of lysed cells, the yield of mRNA decreases.

Another common approach for direct mRNA purification is, as mentioned above, to use guanidinium isothiocyanate (GTC) and sarkosyl. A GTC-buffer system is preferred by most researchers due to the ability of this chaotropic salt to inhibit RNases. This may also be used in combination with the magnetic bead approach. However, the viscosity of cell lysates in 4M GTC is high and the beads are not effectively attracted by the magnet, resulting in an increased risk for DNA contamination, both for beads and other solid phases, and lower yields.

More recently, other methods have been proposed which rely upon the use of a solid phase. In US-A-5,234,809, for example, is described a method where nucleic acids are bound to a solid phase in the form of silica particles, in the presence of a chaotropic agent such as a guanidinium salt, and thereby separated from the remainder of the sample. WO 91/12079 describes a method whereby nucleic acid is trapped on the surface of a solid phase by precipitation. Generally speaking, alcohols and salts are used as precipitants.

Although such methods speed up the nucleic acid separation process, there are disadvantages associated with the use of alcohols, chaotropes, and other similar agents. Chaotropes require to be used at high molarity, resulting in viscous solutions which may be difficult to work with, especially in RNA work. Amplification procedures such as PCR, and other enzyme-based reactions, are very sensitive to the inhibitory or otherwise interfering effects of alcohols and other agents. Moreover, the drying of the nucleic acid pellet

which is necessary following alcohol precipitation and the problems with dissolving nucleic acids, are also known to lead to artefacts in enzyme-based procedures such as PCR. Since such procedures are now a mainstay of molecular biology, there is a need for improved methods of nucleic acid isolation, and particularly for methods which are quick and simple to perform and which avoid the use of chaotropic agents or alcohol precipitation. There is also a need for a method which allows for differentiation between RNA and DNA and permits a separate isolation of both types of nucleic acid from the same sample. The present invention seeks to provide such methods.

In particular, it has now been found that nucleic acid may be isolated from a sample in a form suitable for amplification or other downstream processes, by a simple and easy to perform procedure which involves treating the sample with detergent and allowing the nucleic acid to bind to a solid support, whereupon the nucleic acid may be readily separated from the sample, eg. by removal of the support. The binding of the nucleic acid is independent of its sequence.

In one aspect, the present invention thus provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.

The nucleic acid may be DNA, RNA or any naturally occurring or synthetic modification thereof, and combinations thereof. Preferably however the nucleic acid will be DNA, which may be genomic, or, cDNA, and single or double stranded or in any other form.

Where the method of the invention is used to isolate DNA, it may conveniently be coupled with a further step to isolate RNA from the same sample. The

use of the method in such two-step RNA separations will be described in more detail below.

The samples may be any material containing nucleic acid, including for example foods and allied products, clinical and environmental samples. However, the sample will generally be a biological sample, which may contain any viral or cellular material, including all prokaryotic or eukaryotic cells, viruses, bacteriophages, mycoplasmas, protoplasts and organelles. Such biological material may thus comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, protozoa etc. Representative samples thus include whole blood and blood-derived products such as plasma, serum and buffy coat, urine, faeces, cerebrospinal fluid or any other body fluids, tissues, cell cultures, cell suspensions etc.

The sample may also include relatively pure starting materials such as a PCR product, or semi-pure preparations obtained by other nucleic acid recovery processes.

The nucleic acid-containing sample may, generally speaking, simply be contacted with the detergent, and a solid phase which may be added to the sample prior to, simultaneously with, or subsequently to the detergent. If necessary, this may be preceded by one or more separate steps to disrupt structural components such as cell walls or to achieve lysis. Procedures for achieving this are well known in the art. Thus, for example, although some cells eg. blood cells, may be lysed by the detergent alone, other cells, eg. plant or fungal cells or solid animal tissues may require more vigorous treatment such as, for example, grinding in liquid nitrogen, heating in the presence of detergent, alkaline lysis in the presence of detergent. For samples in the form of paraffin sections and such like, lysis (and melting of the paraffin) may be effected by

heating, for example using a microwave oven (Banerjee, S.K. et al., 1995, Biotechniques 18: 769-773). Also, certain more compact tissues may require enzyme treatment, for example using proteinase K to obtain sufficient release of nucleic acid. The various components are mixed and simply allowed to stand for a suitable interval of time to allow the nucleic acid to bind to the support. Conveniently, if other agents such as enzymes eg. proteinase K are being used, they may be included in with the detergent. The support is then removed from the solution by any convenient means, which will depend of course on the nature of the support, and includes all forms of withdrawing the support away from the sample supernatant, or vice versa, for example centrifugation, decanting, pipetting etc.

The conditions during this process are not critical, and it has been found convenient, for example, simply to mix the sample with the detergent in the presence of a solid phase, and allow it to stand at room temperature, for 5 to 20 minutes, before separating. As mentioned above, the reaction time is not critical and as little as 5 minutes is often enough. However, if convenient, longer periods may be used, eg. 0.5 to 3 hours, or even overnight. Mixing can be done by any convenient means, including for example simple agitation by stirring or vortexing. Also, if desired, higher or lower temperatures may be used, but are not necessary.

The detergent may be any detergent, and a vast range are known and described in the literature. Thus, the detergent may be ionic, including anionic and cationic, non-ionic or zwitterionic. The term "ionic detergent" as used herein includes any detergent which is partly or wholly in ionic form when dissolved in water. Anionic detergents have been shown to work particularly well and are preferred. Suitable anionic detergents include for example sodium dodecyl sulphate (SDS) or other alkali metal alkylsulphate salts or

similar detergents, sarkosyl, or combinations thereof.

Conveniently, the detergent may be used in a concentration of 0.2 to 30% (w/v), eg. 0.5 to 30%, preferably 0.5 to 15%, more preferably 1 to 10%. For anionic detergents concentrations of 1.0 to 5% eg. 0.5 to 5% have been shown to work well.

The detergent may be supplied in simple aqueous solution, which may be alkaline or acidic, or more preferably in a buffer. Any suitable buffer may be used, including for example Tris, Bicine, Tricine, and phosphate buffers. Conveniently, a source of monovalent cations, eg. a salt, may be included to enhance nucleic acid capture, although this is not necessary. Suitable salts include chloride salts, e.g. sodium chloride, lithium chloride etc. at concentrations of 0.1 to 1M, eg. 250 to 500 mM. As mentioned above, other components such as enzymes, may also be included.

Other optional components in the detergent composition include chelating agents eg. EDTA, EGTA and other polyamino carboxylic acids conveniently at concentrations of 1 to 50 mM etc., reducing agents such as dithiotreitol (DTT) or β -mercaptoethanol, at concentrations of for example 1 to 10 mM.

Preferred detergent compositions may for example comprise:

100 mM Tris-HCl pH 7.5

10 mM EDTA

2% SDS

or:

100mM TrisCl pH 7.5

10mM EDTA

5% SDS

10mM NaCl

or:

100mM TrisCl pH 7.5

500mM LiCl

10mM EDTA

1% LiDS

The detergent functions in the method to lyse the nucleic acid containing material, eg. the cells and nuclei to release the nucleic acid. The detergent is also believed to help to disrupt the binding of proteins, eg. DNA-binding proteins, to the nucleic acid and to reduce the problem of contaminants in the sample sticking to the solid support.

The solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation etc. These may take the form of particles, sheets, gels, filters, membranes, fibres, capillaries, or microtitre strips, tubes, plates or wells etc.

Conveniently the support may be made of glass, silica, latex or a polymeric material. Preferred are materials presenting a high surface area for binding of the nucleic acid. Although not wishing to be bound by theoretical considerations, it is believed that the nucleic acid binding process may be assisted by the nucleic acid "wrapping around" the support. Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.

Conveniently, a particulate solid support used according to the invention will comprise spherical beads. The size of the beads is not critical, but they may for example be of the order of diameter of at least 1 and preferably at least 2 μm , and have a maximum diameter of preferably not more than 10 and more preferably not more than 6 μm . For example, beads of diameter 2.8 μm and 4.5 μm have been shown to work well.

Monodisperse particles, that is those which are

- 10 -

substantially uniform in size (eg. size having a diameter standard deviation of less than 5%) have the advantage that they provide very uniform reproducibility of reaction. Monodisperse polymer particles produced by the technique described in US-A-4336173 are especially suitable.

Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno Particles AS (Lillestrøm, Norway) as well as from Qiagen, Pharmacia and Serotec.

However, to aid manipulation and separation, magnetic beads are preferred. The term "magnetic" as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field. In other words, a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the nucleic acid binding step, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may degrade nucleic acids.

Thus, using the method of the invention, the magnetic particles with nucleic acid attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.

Especially preferred are superparamagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during reaction can be avoided, thus ensuring uniform and nucleic acid extraction. The well-known magnetic particles sold by Dynal AS (Oslo, Norway) as

- 11 -

DYNABEADS, are particularly suited to use in the present invention.

Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to US patents 4,336,173, 4,459,378 and 4,654,267. Thus, beads, or other supports, may be prepared having different types of functionalised surface, for example positively charged or hydrophobic. Weakly and strongly positively charged surfaces, weakly negatively charged neutral surfaces and hydrophobic surfaces eg. polyurethane-coated have been shown to work well.

It is also possible to use solid supports which have been modified to permit the selective capture of desired cells, viruses etc. containing the nucleic acid. Thus for example, supports carrying antibodies, or other binding proteins, specific for a desired cell type may be used. This may introduce a degree of selectivity to the isolation of the nucleic acid, since only nucleic acid from a desired target source within a complex mixture may be separated. Thus for example, such a support may be used to separate and remove the desired cell type etc. from the sample, following which, the detergent is added to achieve lysis, release of the nucleic acid, and binding to the support.

The preparation of such selective cell capture matrices is well known in the art and described in the literature.

Likewise, the support may be provided with binding partners to assist in the selective capture of nucleic acids. For example, complementary DNA or RNA sequences, or DNA binding proteins may be used, or viral proteins binding to viral nucleic acid. The attachment of such proteins to the solid support may be achieved using techniques well known in the art.

Although not necessary, it may be convenient to introduce one or more washing steps to the isolation

- 12 -

method of the invention, for example following separation of the support from the sample. In the case of magnetic beads, this may conveniently be done before releasing the DNA from the beads. Any conventional washing buffers or other media may be used. Generally speaking, low to moderate ionic strength buffers are preferred eg. 10 mM Tris-HCl at pH 8.0/10mM NaCl. Other standard washing media, eg. containing alcohols, may also be used, if desired.

Following the separation step, and any optional washing steps which may be desired, the support carrying the nucleic acid may be transferred eg. resuspended or immersed into any suitable medium eg. water or low ionic strength buffer. Depending on the support and the nature of any subsequent processing desired, it may or may not be desirable to release the nucleic acid from the support.

In the case of a particulate solid support such as magnetic or non-magnetic beads, this may in many cases be used directly, for example in PCR or other amplifications, without eluting the nucleic acid from the support. Also, for many DNA detection or identification methods elution is not necessary since although the DNA may be randomly in contact with the bead surface and bound at a number of points by hydrogen bonding or ionic or other forces, there will generally be sufficient lengths of DNA available for hybridisation to oligonucleotides and for amplification.

However, if desired, elution of the nucleic acid may readily be achieved using known means, for example by heating, eg. to 65°C for 5 to 10 minutes, and following which the support may be removed from the medium leaving the nucleic acid in solution. Such heating is automatically obtained in PCR by the DNA denaturation step preceding the cycling program.

If it is desired to remove RNA from DNA, this may be achieved by destroying the RNA before the DNA

separation step, for example by addition of an RNAase or an alkali such as NaOH.

Alternatively, as mentioned above, the method of the invention may be used to separate sequentially DNA and RNA from the sample. It may also be used to remove DNA from a sample in an RNA purification procedure.

Conveniently, the sequential separation may take place using two different solid phases, for example solid supports which can differentiate between DNA and RNA. Thus, such a method may comprise carrying out a first step separation to isolate DNA as described above. A further solid support can then be added to the sample to capture the RNA remaining in the sample, either by using a solid support that can bind the RNA or any remaining nucleic acid, or a solid support that can capture specific RNA molecules (eg. by carrying a complementary nucleic acid probe), or a subset of RNA molecules eg. polyadenylated RNA. In this way it is possible rapidly to isolate and separate DNA and RNA or subsets of both from the same sample. This may be useful, for example by measuring the isolated DNA to estimate the amount of cells used for RNA extraction, which will give a reference between different samples.

However, the DNA isolation procedure of the invention may also readily be combined, as a preliminary step, with other conventional RNA purification procedures, for example DNA isolation with detergent according to invention may be carried out before a selective RNA precipitation step, for example using LiCl or before RNA separation using GTC and sarkosyl.

In a representative procedure, the sample is lysed in the presence of detergent and the DNA is allowed to bind to a solid support, whereupon the DNA may readily be separated from the sample by removal of the support. If desired, the DNA can rapidly and easily be further handled for amplification or other downstream processes. The RNA may then be isolated. This can be by a solid

phase based system as described above, including a repetition of the method of the invention, or by conventional techniques such as extractions, precipitations or affinity chromatography.

A particularly advantageous embodiment of the invention is to use the isolation method of the invention to remove DNA from a sample prior to isolation of RNA, such that the viscosity of the lysed sample is reduced and a specific isolation of RNA molecules is favoured which again reduces or avoids the possibility for DNA contamination of the RNA. Such a method also has the advantage of being quick to perform.

The invention is advantageously amenable to automation, particularly if particles, and especially, magnetic particles are used as the support.

The various reactants and components required to perform the method of the invention may conveniently be supplied in kit form. Such kits represent a further aspect of the invention.

At its simplest, this aspect of the invention provides a kit for isolating nucleic acid from a sample comprising a solid support and one or more detergents.

Optionally included in such a kit may be buffers, salts, lysis agents eg. proteinases, chelating agents and reducing agents.

For isolation of RNA, the kits may further comprise means for isolating RNA eg. a second solid support for isolating RNA, for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.

The invention will now be described in more detail in the following non-limiting Examples with reference to the drawings in which:

Figure 1 shows as optical density scan of DNA isolated as described in Example 1 (ordinate shows absorbance (OD), abscissa shows wavelength (nm)) .

- 15 -

Maximum absorbance (0.427) at 257.6 nM; minimum absorbance (0.292) at 236.4 nM; at a threshold of 0.100;

Figure 2 shows gel electrophoresis of a sample of DNA isolated as described in Example 1 (lane 1: isolation; lane 2: λ Hind III (molecular weight marker));

Figure 3 shows agarose gel electrophoresis of the PCR product of Example 2 (lane 1: PCR product; lane 2: λ Hind III; lane 3: negative PCR control); and

Figure 4 shows agarose gel electrophoresis of the PCR product of Example 5 (lane 1: λ Hind III; lanes 2 and 3: isolations A and B respectively; lanes 4 and 5: negative control; lane 6: λ Hind III).

Figure 5 show the comparison between traditionally isolated DNA and DNA isolated with Dynabeads DNA DIRECT. Panel I shows the amount of genomic DNA isolated from 10 μ l of whole blood with Dynabeads DNA DIRECT including the optional elution step (lanes 1 and 2), with Dynabeads DNA DIRECT with the elution step omitted (lanes 3 and 4), and with traditional DNA isolation (lanes 5 and 6). The molecular weight marker in lane 7 is λ HindIII. Panel II shows the integrity of DNA isolated by Dynabeads DNA DIRECT. Lanes 1 and 2 show AMXY PCR from 20 ng of DNA isolated with Dynabeads DNA DIRECT from a male and female donor respectively. Lanes 4 and 5 show AMXY PCR from 200 ng DNA isolated by traditional methods from a female and a male donor respectively. Lane 3 is the negative control.

Figure 6 shows the reproducibility of Dynabeads DNA DIRECT. The figure shows five independent Dynabeads DNA DIRECT isolations from each of two donors. Half of the DNA obtained from 10 μ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Molecular weight markers are λ HindIII (lanes marked M) or 100 bp ladder (lane marked L).

Figure 7 shows the effect of different anticoagulants. The figure shows Dynabeads DNA DIRECT isolations from whole blood that is not anticoagulated and from blood anticoagulated with EDTA, citrate, or heparin. The two isolations from blood with the same anticoagulant were performed on blood from different donors (A or B). One quarter of the DNA obtained from 10 μ l of blood is shown in the upper part of the figure, except for heparin, where half the DNA obtained from 5 μ l is shown. 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure, except for heparin, where 20% of the isolated DNA was used as starting material.

Figure 8 shows the effect of sample storage conditions. Panel I shows Dynabeads DNA DIRECT isolations from EDTA blood that has been used fresh, refrigerated for 4 days, or frozen for 4 days. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows Dynabeads DNA DIRECT isolations from citrate blood that has been used fresh or air dried and rehydrated. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.

Figure 9 shows Dynabeads DNA DIRECT from bone marrow and culture cells. Panel I shows Dynabeads DNA DIRECT isolations from 1, 2 and 5 μ l of bone marrow from each of two donors. A or B above the lanes denote the identity of the donor. Half of the DNA obtained is shown in the upper part of the figure, 20% of the

product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows two Dynabeads DNA DIRECT isolations from 4×10^5 Daudi cells. One tenth of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 1 μ l of a total of 120 μ l isolated DNA is shown in the lower part of the figure. The molecular weight marker is λ HindIII for the genomic DNA and 100 bp ladder for the PCR products.

Figure 10 shows Dynabeads DNA DIRECT from formalin fixed, paraffin embedded material. Lane A is 20% of the PCR product from a reaction started with DNA isolated by DNA DIRECT from a formalin fixed, paraffin embedded section of liver. Lane M is molecular weight marker (100 bp ladder), lane B is positive control (PCR from 20 ng human DNA), and lane C is negative control (PCR from water).

Figure 11 shows Dynabeads DNA DIRECT for mRNA purification. mRNA was isolated from 1 million Daudi cells per sample with Dynabeads Oligo(dT)₂₅ after removal of DNA with Dynabeads DNA DIRECT. Increasing amounts of DNA DIRECT Dynabeads were used to remove genomic DNA; 1 mg in lane 1 and 2; 2 mg in lane 3 and 4; 5 mg in lane 5 and 6 and 10 mg in lane 7 and 8. Lane 9 and 10 are controls where no DNA was removed before direct mRNA purification. The extra bands on the top of the picture show contaminating genomic DNA in lane 9 and 10. The two strong bands in all lanes represent ribosomal RNA.

Figure 12 shows the results of DNA isolation and PCR amplification from (A) bacteria, (B) fungi, (C) algae and (D) plants. For all samples, DNA was isolated with 200 μ l DNA DIRECT (one sample test) and 20% of the isolated DNA and 10% of the PCR products were analysed by agarose electrophoresis. For bacteria, 2.5% of the isolated DNA was used per PCR reaction, for the other samples 5% was used. 16S rRNA regions were amplified from bacterial genomic DNA and from algae chloroplast

- 18 -

DNA. From fungi- and algae genomic DNA, 18S rDNA were amplified. Amplification of the group I intron chloroplast trnL and parts of the genomic B15C gene are shown for plants. The negative controls are PCR on
5 samples without DNA prepared in the same way as the other reactions.

Example 1DNA isolation from cell culture

5 4×10^6 HL60 cells were washed twice in PBS and pelleted.
The pellet was dissolved in 10 μ l PBS, and 1 mg of
Dynabeads® M-280* obtainable by autoclaving a suspension
of Dynabeads® M-280 tosylactivated (available from DYNAL
A/S, Oslo, Norway) in water) resuspended in 0.1 ml lysis
10 buffer [5% SDS/10 mM TrisCl pH 8.0/1 mM EDTA] was added.
This was followed immediately by the addition of 1 ml
lysisbuffer, and the suspension was incubated for 5
minutes at room temperature, after which the Dynabeads®,
with bound DNA was attracted to a magnet and the liquid
15 phase removed. The solid phase was then washed twice
with 1 ml washing buffer [50 mM NaCl/10 mM TrisCl pH
8.0/1 mM EDTA]. Finally, the beads, with bound DNA,
were resuspended in 0.1 ml water, and incubated for 5
minutes at 65°C. The beads were attracted to a magnet,
20 and the liquid phase withdrawn. The liquid phase was
then analyzed for its DNA content. Results from an
optical density scan (Fig. 1) are in accordance with
pure DNA. The OD_{260}/OD_{280} ratio is 1.72; pure DNA in
water or TE has a ratio of 1.7 - 1.9. With pure DNA,
25 the concentration can be determined from the OD_{260} of the
solution. A 50 μ g/ml solution has $OD_{260} = 1.0$. From the
 OD_{260} measurement (Table 1) of 0.436 (0.1 ml total
volume, 10 mm lightpath), the yield can be calculated to
2.18 μ g DNA, 82% of the 2.67 μ g that was the estimated
30 DNA content of the starting material. Gel
electrophoresis of a sample of the isolated DNA (Fig. 2)
shows that most of it is in a high molecular weight form
(>20 kb).

- 20 -

Table 1

PERKIN-ELMER LAMBDA BIO UV/VIS SPECTROMETER
APPLICATION NO. 3: RATIO 260/280 NM

5					
	SAMPLE	CYCLE	WAVELENGTH	DATA	UNIT
		15:50	AUTOZERO		
	004	15:56	260.0 nm	0.436	ABS
			280.0 nm	0.253	ABS
10			RATIO	1.723	RAT

Example 2

15 Isolation of DNA from whole blood and enzymatic
application without elution

5 μ l whole blood (EDTA blood) was lysed in 50 μ l 5% SDS
and 50 μ g Dynabeads® M-280* in 5 μ l of PBS was added.
20 The lysate was incubated for 1 minute at room
temperature before 0.5 ml TrisCl pH 7.5 was added. The
lysate was then incubated for 1 minute further at room
temperature before the beads with bound DNA were
attracted to a magnet and the liquid phase removed. The
25 beads were then washed once with 0.5 ml 10 mM TrisCl pH
7.5, before the beads with bound DNA was resuspended in
40 μ l TE (10 mM TrisCl pH 8.0/1mM EDTA). 4 μ l of the
isolation was used in starting material for PCR (GAPDH
PCR as described in Example 7). The PCR reaction gave
30 large amounts of product, as visualised on agarose gel
electrophoresis (Fig. 3). 10 μ l of a 50 μ l PCR reaction
was loaded on the gel.

Example 3

Example 1 was repeated using the following combination of lysis buffers and washing buffers, and the following results were obtained:

(where +++ indicates very good DNA isolation)

	<u>Lysis buffer</u>	<u>Washing buffer</u>	<u>Result</u>
10	2% SDS	50 mM NaCl/1 x TE	+++
	2% SDS/1 x TE	50 mM NaCl/1 x TE	+++
	2% SDS/1 x TE/10 mM NaCl	50 mM NaCl/1 x TE	+++
	5% SDS	50 mM NaCl/1 x TE	+++
	5% SDS/1 x TE	50 mM NaCl/1 x TE	+++
15	5% SDS/1 x TE/10 mM NaCl	50 mM NaCl/1 x TE	+++
	1% LiDS/10 x TE/0.5 M LiCl	50 mM NaCl/1 x TE	+++
	1% LiDS/10 x TE/0.5 M LiCl	150 mM LiCl/1 x TE	+++
	5% LiDS	150 mM LiCl/1 x TE	+++
	5% SDS	150 mM LiCl/1 x TE	+++
20	1% Sarcosyl	150 mM LiCl/1 x TE	+++

1 x TE is 10 mM TrisCl pH 8.0/1 mM EDTA, 10 x TE is 100 mM TrisCl pH 8.0/10 mM EDTA

25

Example 4

Following the procedure of Example 1, similar results may be achieved using Dynabeads® M-450 uncoated (Dynal A/S, Oslo, Norway)

30

EXAMPLE 5Isolation of DNA from CD2 positive cells obtained from blood with immunomagnetic separation

5

This experiment consisted of two identical isolations. 50 μ l blood was mixed with 50 μ l PBS [150 mM NaCl/10 mM NaH₂PO₄/Na₂HPO₄, pH 7.4] and 10 μ l (4×10^6 beads) Dynabeads[®] M-450 Pan-T (CD2) (available from Dynal AS, Oslo, Norway). The mixture was then incubated for 30 minutes at room temperature with gentle tilting and rotation. The cell/beads complex was attracted to a magnet and the fluid withdrawn. The cell/beads complex was then washed four times in 200 μ l PBS, before 200 μ g Dynabeads[®] M-280* (as above) and 200 μ l lysisbuffer [100 mM Tris-HCl, pH 8.0/500 mM LiCl/10 mM EDTA, pH 8.01/1% LiDS] was added. The mixture was incubated for 5 minutes at room temperature, before the DNA/beads complex was attracted to a magnet, and the supernatant withdrawn. The DNA/beads complex was washed twice with 200 μ l washing buffer [10 mM Tris-HCl, pH 8.0/150 mM LiCl/1 mM EDTA, pH 8.0] and resuspended in 50 μ l water. After 5 minutes at 65°C, the beads were attracted to a magnet and the supernatant transferred to a new tube. 5 μ l of the supernatant was used as template for polymerase chain reaction (GAPDH PCR as described in Example 7), which gave large amounts of product, as visualised on agarose gel electrophoresis (Fig. 4).

30

EXAMPLE 6Comparison of yield and integrity between DNA isolated by a traditional method and the present method

35

Using a traditional method based on phenol extraction and ethanol precipitation, genomic DNA was isolated from 5 ml of EDTA anticoagulated blood. Four isolations from

- 23 -

10 μ l of the same blood sample were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway, containing beads equivalent to Dynabeads® M-280* as described in Example 1). The DNA
5 from two of the isolations was eluted for 5 minutes at 65°C, while the DNA from the other two isolations was left in the presence of the Dynabeads. All the DNA from the four Dynabeads DNA DIRECT isolations was loaded onto an agarose gel, as was 0.2% of traditionally isolated
10 DNA. The fraction of the traditionally isolated DNA loaded corresponds to the yield from 10 μ l of blood (0.2% of 5 ml).

Traditional DNA isolation was performed according to the
15 method of John and coworkers (John, S.W.M., G. Weitzner, R. Rosen and C.R. Scriver. 1991. A Rapid Procedure for Extracting Genomic DNA from Leukocytes. Nucl. Acid. Res. 19(2):408).

20 With Dynabeads DNA DIRECT, lysis of the blood was obtained by mixing 200 μ l (one sample test) of Dynabeads DNA DIRECT with 10 μ l of blood in a 1.5 ml microcentrifuge tube (200 μ g uncoated Dynabeads in Lysis/binding buffer). Lysates were then left on the
25 bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.

The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the
30 lysate was aspirated and discarded.

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex
35 was resuspended in 10 μ l of TE pH 8.0 (provided in the kit).

When elution was performed, it consisted of heating the suspension to 65°C for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.

5

The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

10

The result of this experiment is shown in panel I of figure 5. The yield per μ l blood is similar with the two methods (lane 1-4 vs lane 5-6), and very little DNA is lost during the elution step (lane 1-2 vs lane 3-4).

15

The molecular weight of the DNA from both methods is more than 20 kb, as it runs slower than the 23.13 kb band of the λ HindIII molecular weight marker.

20

DNA DIRECT was used to isolate DNA from ACD blood from two different donors, one male and one female. From each of the isolations, 10 % was used as starting material for PCR amplification of an amplicon in the X-Y homologous amelogenin (AMXY) gene (Akane, A., K, Matsubara, H. Nakamura, S. Takahashi and K. Kimura.

25

1994. Purification of Highly Degraded DNA by Gel Filtration for PCR. BioTechniques 16 (2):235-238), as was 200 ng from each of two traditional DNA isolations.

30

DNA DIRECT and traditional DNA isolation was performed as described in the first part of this example.

35

All PCR reactions were performed in a 50 μ l reaction volume, 10 x PCR buffer (Perkin Elmer) was added to a final concentration of 1 x, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers AMXY-1F (5'-CTGATGGTTGGCCTCAAGCCT-GTG-

3') and AMXY-4R (5'-TTCATTGTAAGAGCAAAGCAAACA-3') were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the AMXY amplicon were 4 min at 94°C, 38 X [30 sec at 94°C, 30 sec at 55°C, 1 min at 72°C], 10 min at 72°C.

10 µl of the 50 µl PCR reactions were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

The results of this experiment are shown in panel II of figure 5. The X-Y homologous amelogenin gene is known to be sensitive to DNA degradation (Akane et al 1994, supra). With increasing degradation, the 908 bp long X band gets progressively weaker as compared to the 719 bp long Y band. From panel II of figure 5 it is apparent that the relative strength of the X and Y bands is comparable for DNA isolated with Dynabeads DNA DIRECT and the traditional method, indicating that the degree of degradation is the same with the two methods. The PCR reactions from traditionally isolated DNA gives somewhat more product than does the reactions from DNA DIRECT isolated DNA. The reason for this is that ten times more template is used in the PCR reactions from traditionally isolated DNA than in the PCR reactions from DNA DIRECT isolated DNA.

30	Lysis/binding buffer:	0.5 M LiCl 1 % LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT)
35	Washing buffer:	0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA

Example 7Five independent DNA isolations from blood samples from each of two donors

5

For this experiment, we used Dynabeads DNA DIRECT kit, which is commercially available from Dynal AS, Oslo, Norway. Buffer compositions are as described in example 6.

10

Five DNA isolations were performed from each of two citrate treated blood samples of relatively low white blood cell counts (sample A: 3.6×10^6 cells/ml, sample B: 2.6×10^6 cells/ml).

15

Lysis of the blood was obtained by mixing 200 μ l (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.

20

The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.

25

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μ l of TE pH 8.0 (provided in the kit).

30

This resuspension was used for PCR and gel electrophoresis without any elution.

35

From each isolation, 10 % was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. All PCR reactions were performed in a 50 μ l reaction volume, 10 x PCR buffer (Perkin Elmer) was added to a final

- 27 -

concentration of 1 x, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5'-ACAGTCCATGCCATCACTGCC-3') and GAPDH-Reverse (5'-GCCTGCTTCACCACCTTCTTG-3') were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94°C, 34 X [30 sec at 94°C, 30 sec at 61°C, 1 min at 72°C], 10 min at 72°C.

Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 µl of the 50 µl reaction was loaded on to an agarose gel, as was 50 % of the isolated genomic DNA. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

The results of this experiment are shown in figure 6. No significant variation between the different isolations can be observed. Similar results were obtained with other coagulants as well as from donors with higher white blood cell counts.

25 EXAMPLE 8

DNA isolation from blood with different anticoagulants

Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from untreated whole blood as well as blood anticoagulated with EDTA, Citrate or Heparin. From each type of starting material, two separate isolations were performed, with blood from different donors. The buffer components in the kit are as described in example 6.

Lysis of the DNA containing cells from blood was

- 28 -

obtained by mixing 200 μ l (one sample test) of Dynabeads DNA DIRECT with 5 μ l Heparin blood or 10 μ l of other blood samples in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.

The DNA/Dynabeads complex was attracted to a magnet (Dyna'l's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 20 - 40 μ l of TE pH 8.0 (provided in the kit). We used 40 μ l as the standard volume, but 20 μ l if the starting material was Heparin blood.

From each isolation, 10 % (20 % from the Heparin samples) was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. PCR was performed directly on the suspension in TE, with the Dynabeads present. All PCR reactions were performed in a 50 μ l reaction volume, 10 x PCR buffer (Perkin Elmer) was added to a final concentration of 1 x, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5'-ACAGTCCATGCCATCACTGCC-3') and GAPDH-Reverse (5'-GCCTGCTTCACCACCTTCTTG-3') were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94°C, 34 X [30 sec at 94°C, 30 sec at 61°C, 1 min at 72°C], 10 min at 72°C.

10 μ l of the 50 μ l reaction was loaded on to an agarose

- 29 -

gel, as was 25 % (50 % from the Heparin samples) of the isolated genomic DNA. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

The results of this experiment are shown in figure 7. As the isolations from Heparinized samples were from only 5 μ l of blood, using 20 % of the DNA from these isolations as starting material for PCR is comparable to using 10 % from the other isolations, that are all from 10 μ l blood. When this is taken into consideration, it is apparent that the type of anticoagulant used does not significantly affect the result.

In the experiment just described, Lithium Heparin was used. In this system, similar results are obtained with Lithium and Sodium Heparin, even though Lithium Heparin has been shown to have inhibitory effects in other systems (Panaccio, M., M. Georgesz and A.M. Lew. 1993. FoLT PCR: A Simple PCR Protocol for Amplifying DNA Directly from Whole Blood. BioTechniques 14(3): 238-243). DNA DIRECT also performs well on blood anticoagulated with ACD (panel II of figure 5) or CPD (data not shown).

Example 9

Isolation of DNA from blood samples stored under different conditions

Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from EDTA blood from two different donors. What was remaining of the blood samples were then divided into two, one part that was stored at +4°C and one that was

stored at -20°C. After 4 days, the frozen samples were thawed, and DNA was isolated from both the frozen samples and the samples that had been kept at +4°C. The buffer components of the kit are as described in example 6.

Lysis of the blood was obtained by mixing 200 µl (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.

The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 µl of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.

From each of the 6 isolations (fresh, refrigerated, and frozen), 10 % was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 µl of the 50 µl reaction was loaded on the gel, as was 50 % of the isolated genomic DNA. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel I of figure 8. No adverse effect of 4 days storage at +4 or -20°C was observed in this system.

- 31 -

Using Dynabeads DNA DIRECT as described earlier in this example, DNA was isolated from two citrate treated blood samples, and from the same two samples 10 μ l was spotted on a plastic surface and allowed to air dry at room temperature. The dried blood spots were transferred to 1.5 ml tubes, 40 μ l PBS was added, and the tubes were left at room temperature with gentle agitation for 90 min, before DNA was isolated with Dynabeads DNA DIRECT. From each of the 4 isolations (fresh and dried), 10 % was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μ l of the 50 μ l reaction was loaded on the gel, as was 50 % of the isolated genomic DNA. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel II of figure 8. The yield from dried blood is good and the isolated DNA is suitable for PCR.

Example 10

DNA isolation from Bone marrow and Culture cells

DNA ISOLATIONS FROM BONE MARROW

1, 2, and 5 μ l of heparinized bone marrow from each of two healthy donors were used as starting material for DNA isolation with DNA DIRECT. The buffer components are as described in example 6. Lysis of the bone marrow was obtained by mixing 200 μ l (one sample test) of Dynabeads DNA DIRECT with 1-5 μ l of heparinized bone marrow in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.

- 32 -

The DNA/Dynabeads complex was attracted to a magnet (Dyna'l's Magnetic Particle Collector E(MPC-E)), and the lysate was aspirated and discarded.

5 The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μ l of TE pH 8.0 (provided in the kit).
10 Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.

From each of the 6 isolations, 10 % was used as starting material for PCR amplification of the GAPDH amplicon as
15 described in example 8.

Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μ l of the
20 50 μ l reaction was loaded on to an agarose gel, as was 50 % of the isolated genomic DNA. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

25 The results of this experiment are shown in panel I of figure 9. It is apparent from panel I of figure 9 that the yield per volume starting material is higher from bone marrow than from blood (figures 5-8). This is to be expected, since the concentration of DNA containing
30 cells is much higher in bone marrow than in blood. 5 μ l of bone marrow is close to the upper limit of what can be handled by 1 sample test of DNA DIRECT. A good correlation between sample size and DNA yield is observed in the 1 to 5 μ l sample size interval, but even
35 the yield from 1 μ l is sufficient for at least 10 PCR reactions.

- 33 -

DNA ISOLATION FROM CULTURED CELLS

Two samples of 4×10^5 Daudi cells were used as starting material for DNA isolation with DNA DIRECT. DNA
5 isolation from 4×10^5 cultured cells (cell line Daudi) was performed as described above, except that 1 ml (five sample tests) of Dynabeads DNA DIRECT was used. Accordingly, the washing steps were performed in 1 ml washing buffer. The DNA/Dynabeads complex was
10 resuspended in 120 μ l TE, and as for bone marrow, no elution step was performed after the resuspension.

From each of the isolations, 1 μ l of a total of 120 μ l was used as starting material for PCR amplification of
15 the GAPDH amplicon, as described in Example 8.

Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μ l of the
20 50 μ l reaction was loaded on to an agarose gel, as was 10 % of the isolated genomic DNA. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.

25 The results of this experiment are shown in panel II of figure 9, demonstrating that at least 120 PCR reactions may be run from an isolation of this scale.

Example 11

30

Isolation of DNA from a formalin fixed, paraffin embedded section of liver

35 Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from a formalin fixed, paraffin embedded section of liver. The buffer components of the kit and the bead concentration

- 34 -

are as described in example 6.

Excess paraffin was removed from the edges of the sample with a scalpel blade. Lysis of the sample was obtained
5 by adding 200 μ l (one sample test) of Dynabeads DNA DIRECT to the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads. The lysate, containing DNA and Dynabeads was
10 transferred to a fresh tube, leaving cell debris and paraffin behind.

The DNA/Dynabeads complex was attracted to a magnet (Dyna'l's Magnetic Particle Collector E (MPC-E)), and the
15 lysate was aspirated and discarded.

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was
20 resuspended in 10 μ l of sterile water. This suspension, with the Dynabeads present, was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. The PCR product was visualised on an ethidium bromide stained 1.5% agarose gel. 10 μ l
25 of the 50 μ l reaction was loaded on the gel.

Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The result of this experiment is
shown in figure 10. PCR amplifiable material has clearly
30 been obtained from the formalin fixed, paraffin embedded section of liver.

Example 12:Removal of genomic DNA with DNA DIRECT prior to mRNA isolation.

5

mRNA was isolated from 1 million Daudi cells per sample. The cells were lysed in 0.75 ml Lysis/binding buffer with DNA DIRECT Dynabeads present in the buffer. The samples were incubated for 5 minutes and the

10 DNA-Dynabead complexes were collected by applying a Dynal MPC-E magnet for 2 minutes. Different amounts of DNA DIRECT beads were used to remove genomic DNA; 1, 2, 5 and 10 mg per sample (Figure 11).

15 The lysate from each sample was transferred to new tubes with 1 mg Dynabeads Oligo(dT)₂₅ according to standard procedure (Dynal's mRNA DIRECT kit protocol). The Dynabeads were mixed with the lysate to capture the polyadenylated mRNA by hybridisation for 5 minutes at

20 room temperature. The mRNA-Dynabead complexes were collected with the MPC-E magnet by placing the tubes in the magnetic stand for 2 minutes. The solution was removed and discarded. Washing solution with LiDS (0.75 ml) was added and the beads were washed thoroughly by

25 pipetting up and down. The mRNA-Dynabead complexes were collected with the magnet, and the washing procedure was repeated once with washing buffer with LiDS and twice with washing buffer without detergent. Finally, the purified mRNA was eluted from the Dynabeads in 20 μ l 5

30 mM Tris-HCl pH 7.5 buffer, by incubation at 65° C for 2 minutes. The eluates were analysed by non-denaturing gel electrophoresis in a 1.0 % agarose gel with ethidium bromide. Figure 11 shows the results from this experiment.

35

The EtBr-staining reveals both double-stranded DNA and rRNA due to secondary structure. The two ribosomal RNA

- 36 -

bands are clearly visible in all lanes. In Lane 9-10 in figure 11, some genomic DNA is present as contamination after the mRNA purification procedure. In the recommended mRNA procedure from DYNAL, a DNA-shearing step is introduced after cell lysis, to reduce the possibility of DNA contamination. By using DNA removal with DNA DIRECT beads this shearing step is not necessary.

10	Lysis/binding buffer:	0.5 M LiCl 1 % LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT)
15	Washing buffer with LiDS:	0.15 M LiCl 0.1 % LiDS 10 mM Tris-HCl pH 8.0 1 mM EDTA
20	Washing buffer:	0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA

25 Example 13:

Universal method for DNA isolation:

PCR-ready DNA from bacteria, fungi, algae, plants and vertebrates

30 E. coli and Baceillus cereus were grown overnight at 37°C in LB medium, Agrobacterium tumefaciens was grown overnight in YEB medium for about 40 hours at 28°C (Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour Laboratory, NY.). Cyanobacteria and Prochlorthrix were grown in NIVA medium for 14 days at 18°C using an illumination of 20 micro Einstein (Norwegian Institute

- 37 -

of Water Research, 1991, Culture collection of algae). 20-200 million bacteria or 450,000 cyanobacteria were used per DNA isolation.

5 Agar plates containing 2% malt extract was used for mycelia growth and incubated for 14 days at room temperature. Mycelia was isolated by scraping the surface of the agar plates with a spatula. Fungi fruitbodies were obtained from natural populations. In
10 the range of 1-3 mg air dried and 3-20 mg fresh fungi fruitbodies were used per DNA isolation.

Bakers yeast Saccharomyces cerevisiae was obtained from a commercial supplier. Algae were cultured under
15 illumination in IMR-medium for 7 days (Eppley, R et al., 1967, Exp. Mar. Biol. Ecol. 1, 191-208). Fresh leaves from Arabidopsis thaliana and barley (Hordeum vulgare) were picked from young plants (3 weeks old). Epithelia were obtained from perch (Perca fluviatilis) fins. About
20 1 mg wet weight yeast, 30-100 mg young plant leaves and 100-400 mg perch were used per DNA isolation.

Multicellular tissues with rigid cell walls were mechanically broken to increase DNA yield. Fungi
25 fruitbodies were ground with forceps for about 2 minutes. Plant leaves were homogenised for 2 minutes in liquid nitrogen with a pestle (Kontes Scientific Instruments, Vineland, New Jersey, USA). For all other samples no mechanical work was required for cell
30 breakage.

DNA isolation

DNA isolations were performed using Dynabeads DNA DIRECT
35 (kit, commercially available from Dynal AS, Oslo, Norway). Lysis of the cells and organisms were obtained by mixing 200 μ l of Dynabeads DNA DIRECT (200 μ g uncoated Dynabeads in Lysis/binding buffer) with the

- 38 -

sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 to 15 minutes to allow adsorption of genomic DNA to the Dynabeads. For some bacteria and for plants, incubation
5 at 65°C for 15 minutes was used to improve lysis before the adsorption step.

The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the
10 lysate was aspirated and discarded.

The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex
15 was resuspended in 40 µl of TE pH 8.0 (provided in the kit) by vigorous pipetting. Elution was performed by heating the suspension to 65°C for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the
20 experiments.

The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34
25 Polaroid camera and Polaroid 667 film.

Lysis/binding buffer:	0.5 M LiCl
	1% LiDS
	0.1 M TrisCl pH 7.5
30	10 mM EDTA
	5 mM dithiothreitol (DTT)

Washing buffer:	0.15 M LiCl
	10 mM Tris-HCl pH 8.0
35	1 mM EDTA

For an evaluation of the yield from the DNA DIRECT isolation protocol, standard phenol/chloroform based

- 39 -

methods were used. Algae, vertebrate and bacterial DNA were isolated with the protocol described by Sambrook, J. et al., 1989, *supra*. Cyanobacteria were homogenized with alumina type A-5 (Sigma Chemicals Co., St. Louis, USA) before isolation to ensure complete lysis. Plant and fungi DNA were isolated with the protocol described by Scot, O.R. and Bendich, A.J., 1994, in "Plant Molecular Biology Manual", page D1: 1-8, Kluwer Academic Publisher, Belgium.

PCR amplifications

For each sample type the reproducibility was tested by using separate DNA isolations, serial DNA dilutions and multiple PCR assays. DNA isolation reagents and PCR reagents were controlled for absence of contamination in each separate experiment. All PCR reactions were performed in a 50 μ l reaction volume containing; 15 pmoles primers, 200 μ M dNTP, 10 mM Tris-HCl pH 8.8, 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100, 1 Unit DynaZyme thermostable polymerase (Finnzymes Oy, Finland) and 0.1-5 μ l of isolated DNA. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600.

Amplicons and oligonucleotide primers

All PCR reactions were started with a DNA denaturation step at 94-97°C for 3 to 5 minutes and ended with an extension step at 72°C for 5 minutes.

Bacteria and algae:

The amplicon was a 16S rRNA region corresponding to E. coli base 334 to 939 according to IUD numbering from bacteria and algae chloroplasts (Brosius, J., et al., 1978, Proc. Natl. Acad. Sci., USA, 57, 4801-4805).

Primers: CC 5'-TGTAACGACGGCCAGTCCAGACTCCTACGGGAGGCAGC-3'

CD 5'-CTTGTGCGGGCCCCCGTCAATTC-3'

- 40 -

Primer CC has a 5' end complementary to -21 M13 universal primer, making it suitable for direct DNA sequencing. Amplification: 30 cycles of 96°C for 15 seconds and 70°C for 2 minutes.

5

Algae: An 18S rRNA region was amplified with the primers A and B described by Medlin et al., 1990, Gene, 71, 491-499.

10 Amplification: 35 cycles of 94°C for 30 seconds, 50°C for 1 minute and 72°C for 1 minute.

Fungi: A 18S rRNA region (ca. 600 bp.) was amplified with the primers NS3 and NS4 as described by White et al., 1990. In "PCR Products, a Guide to Methods and Applications" by Innis, M.A. et al., page 315-322, Academic Press, New York.

20 Amplification: 5 cycles of 94°C for 30 seconds, 53°C for 30 seconds and 72°C for 1 minute; followed by 25 cycles of 94°C for 30 seconds, 50°C for 30 seconds increasing with 15 seconds for each cycle, and 72°C for 1 minute.

25 Plants: The tRNL group I intron in chloroplasts were amplified with the primers C and D described by Fangan et al., 1994, BioTechniques 16, 484-494.

Amplification: 30 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute.

30

A part of the Arabidopsis thaliana gene BI5C (800 bp) was amplified with the primers
5'-CGGGATCCCTAGGAGACACGGTGCCG-3' and
5'-GGAATTCGATCGGCGGTCTTGAAAC-3'

35

Amplification: 35 cycles of 94°C for 30 seconds, 59°C for 30 seconds and 72° for 1 minute.

- 41 -

A part of the Barley gene B15C (800 bp) was amplified with the primers 5'-CGGATCCCGTCATCCTCTTCTCGCACCCC-3' and 5'-GGAATTCCTTCTTGGAGGGCAGGTCGGCG-3'.

5 Amplification: 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute.

Perch: Mitochondrial D-loop fragment (800-900 bp) was amplified with the primers HV2 described by Hoelzel et al., 1991, Mol. Biol. Evol., 8, 475-493, and the primer 10 5'-GGTGACTTGCATGTGTAAGTTCA-3'.

Amplification: 30 cycles of 96°C for 1 minute, 52°C for 2 minutes and 72°C for 2 minutes.

15 The amplified fragments were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 x TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 20 film.

The results of the experiments are shown in Figure 12 and Table 2.

25 Bacteria: The standard protocol gave DNA yields in the range of 100-1000 ng for the bacteria tested (Fig. 12A). For some Cyanobacteria there was a substantial increase in DNA yield (from 500 ng to more than 1 mg) by improving the lysis with an extra initial incubation 30 step at 65°C for 15 minutes. In all cases, good amplifications were obtained by using 0.25% of the isolated DNA.

35 Fungi: The highest DNA yield was obtained from dried fruit-bodies (300-500 ng) compared with fresh fruit bodies (100-200 ng) (Fig. 12B). Mycelia gave low DNA recovery probably due to low number of cells per sample. However, in most cases 5% of the isolated DNA was enough

- 42 -

to give nice PCR products (Table 2, Fig. 12B). For fruit bodies, 0.5-5% of DNA was used for each PCR.

5 Algae: All algae tested gave DNA yield in the range of 200-400 ng using the standard protocol and 1 DNA DIRECT sample test (Table 2, Fig. 12C). Nice PCR results were obtained both for amplification of genomic DNA and chloroplast DNA by using 5% of the isolated DNA per PCR reaction.

10

Plants: To obtain good DNA yield from plant leaves homogenization in liquid nitrogen was necessary. An extra initial incubation step at 65°C for 15 minutes also improved the results (Fig. 12D). Nice PCR results
15 were obtained both for amplification of genomic DNA and chloroplast DNA, when 5% of the isolated DNA was used per PCR reaction.

20

Fish: DNA yield of 300-500 ng was routinely obtained from fish epithelia, using the standard protocol and one sample test (Table 2). Mitochondrial DNA was nicely amplified using 5% of the isolated DNA.

25

PCR products from all species tested could easily be directly sequenced by solid-phase sequencing (Hultman et al., 1989, Nucleic Acids Res., 17, 4937-4946).

Table 2: DNA isolation and PCR amplification from different organisms

Species ^a		Sample ^b	DNA yield ^c	Amplicon ^d		PCR product ^e	
				Gen.	Org.		
Bacteria							
<i>Bacillus cereus</i> AH 75 ^a	gram pos.	fresh	+++	16S		+++	
<i>E. coli</i> NovaBlue ^f		fresh	+++	16S		+++	
<i>A. tumefaciens</i> GV 310 ^g	gram neg.	fresh	+++	16S		+++	
<i>Planctothrix agardhii</i> N-C 29		fresh	+++	16S		+++	
<i>P. prolifica</i> N- C320		fresh	+++	16S		+++	
<i>Microcystis aeruginosa</i> N-C 43		fresh	+++	16S		+++	
<i>M. aeruginosa</i> N-C 228/1		Cyanobacteria	fresh	+++	16S		+++
<i>Anabaena bory</i> N-C 246			frozen	+++	16S		++
<i>Phormidium</i> sp N-C 177	frozen		+++	16S		++	
<i>Aphanizomenon</i> sp N-C 103	prochlorothrix	frozen	+++	16S		+++	
<i>P. hollandica</i> N 5/89		frozen	+++	16S		+++	
Fungi							
<i>Cortinarius sanguineus</i>	basidiomycetes	d.fruitb.	+++	18S		+++	
<i>Cortinarius gentilis</i>		d.fruitb.	nt	18S		+++	
<i>Russula integra</i>		f.fruitb.	++	18S		+++	
<i>Laccaria bicolor</i>	ascomycetes	f.mycel	+	18S		+++	
<i>Tricharia ochroleuca</i>		f.mycel	nt	18S		+++	
<i>Verharia calthae</i>		f.mycel	nt	18S		+++	
<i>Peziza vesiculosa</i>		f.mycel	nt	18S		+++	
<i>Saccharomyces cerevisiae</i>		yeast	fresh	+	18S		+++
Algae							
<i>Gyrodinium aureolum</i>	dinoflagellates	fresh	+++	18S/16S		+++ / +++	
<i>Heterocapsa triquetra</i>		fresh	+++	18S/16S		+++ / +++	
<i>Scrtpsiella trochidea</i>		fresh	+++	18S/16S		+++ / +++	
<i>Ceratium strictum</i>	chlorophyta	fresh	+++	18S		+++	
<i>Chlorella vulgaris</i>		fresh	+++	18S		+++	
<i>Clamydomonas reinardii</i>		fresh	+++	18S		+++	
<i>Caullacantus ustulata</i>		phacophyceae	fresh	+++	18S		+++
<i>Chrysochromulina polylepis</i>		crysophyceae	fresh	+++	18S		+++
Plants							
<i>Hordeum vulgare</i> (barly)	monocot	leaf	+++	B15C/mtL		+++ / +++	
<i>Arabidopsis thaliana</i>	dicot	leaf	+++	B15C/mtL		+++ / +++	
Vertebrates							
<i>Perca fluvatilis</i> (perch)	fish	ep.	+++	D-loop		+++	

^a *A. tumefaciens* = *Agrobacterium tumefaciens*,*P. hollandica* = *Prochlorothrix hollandica*.^b d.fruitb = dried fruitbodies, f.mycelia = fresh mycelia, ep. = epithelium.^c Approximate DNA yields relative to standard phenol/chloroform isolations;

+++ : > 80 %, ++ : > 10 %, + : > 1 %, nt. = not tested.

^d Gen. = genomic DNA, Org. = organelle DNA from chloroplasts (algae and plants) and mitochondria (fish).^e Amplicons as described in example 13.

Claims

1. A method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.
2. A method as claimed in claim 1, wherein the nucleic acid is RNA.
3. A method as claimed in claim 1, wherein the nucleic acid is DNA.
4. A method as claimed in claim 1, further comprising an additional step to isolate RNA from the sample.
5. A method as claimed in any one of claims 1 to 4, further comprising one or more additional steps to disrupt structural components in the sample or to achieve lysis of cells in the sample.
6. A method as claimed in any one of claims 1 to 5, wherein the detergent is anionic.
7. A method as claimed in claim 6, wherein the detergent is sodium dodecyl sulphate, or another alkali metal alkylsulphate salt, or sarkosyl.
8. A method as claimed in any one of claims 1 to 7, wherein the concentration of detergent is 0.2 to 30% (w/v).
9. A method as claimed in any one of claims 1 to 8, wherein the detergent is contained in a composition additionally comprising one or more monovalent cations, chelating agents or reducing agents.

- 45 -

10. A method as claimed in any one of claims 1 to 9,
wherein the detergent is used in alkaline solution.

5 11. A method as claimed in any one of claims 1 to 10,
wherein the solid support is particulate.

12. A method as claimed in claim 11, wherein the solid
support comprises magnetic beads.

10 13. A method as claimed in any one of claims 1 to 12,
wherein the solid support has a hydrophobic surface.

14. A method as claimed in any one of claims 1 to 13,
wherein the nucleic acid is eluted from the support,
15 following separation from the sample.

15. A method as claimed in claim 14, wherein the
nucleic acid is eluted by heating.

20 16. A kit for isolating nucleic acid from a sample,
comprising a solid support and one or more detergents as
defined in any one of claims 1 to 13.


25 17. A kit as claimed in claim 16, further comprising
one or more buffers, salts, lysis agents, chelating
agents and/or reducing agents.

18. A kit as claimed in claim 16 or claim 17, further
comprising means for isolating RNA.

30

THIS PAGE BLANK (USPTO)

1/7



THRESHOLD = 0.100

FIG. 1

DATA	WAVELENGTH	CYCLE	SAMPLE
0.427 ABS	257.6 nm (MAX)	15 : 40	004
0.292 ABS	236.4 nm (MAX)		

05 Rev'd PCT/PTO 12 JUN 1997


THIS PAGE BLANK (USPTO)

2 / 7



1 2 3

FIG. 3




1 2

FIG. 2

OFFICE OF PCT/PTO 12 JUN 1997

THIS PAGE BLANK (USPTO)



1 2 3 4 5 6

FIG. 4




FIG. 5

09/06/97 PCT/PTO 12 JUN 1997

THIS PAGE BLANK (USPTO)

4 / 7




FIG. 7




FIG. 6

09 REC'd PCT/PIO 12 JUN 1997

THIS PAGE BLANK (USPTO)

5 / 7




FIG. 9




FIG. 8

09H00 PCT/PTO 12 JUN 1997

THIS PAGE BLANK (USPTO)

6/7

1 2 3 4 5 6 7 8 9 10




FIG. 11

C B M A




FIG. 10

09 R 00 PCT/PTO 12 JUN 1997

THIS PAGE BLANK (USPTO)

7/7




FIG. 12
 SUBSTITUTE SHEET (RULE 26)

09 0000 PCT/PTO 12 JUN 1997

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
FRANK B. DEHN & CO.
Attn. DZIEGLEWSKA, Hanna Eva
179 Queen Victoria Street
LONDON EC4V 4EL
UNITED KINGDOM

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

FILE 61695/502
- 9 AUG 1996
RECEIVED
ANSD

Date of mailing
(day/month/year)

02/08/96

Applicant's or agent's file reference

27.61695/002.hd

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.

PCT/GB95/02893

International filing date

(day/month/year)

12/12/95

Applicant

DYNAL AS et al.

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? To the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2; the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicants's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

**DUE DATES
NOTED**

2/10/96

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

C. van der Vliet
tel: (070) 3403368
The Hague

THIS PAGE BLANK (USPTO)

NOTES TO FORM PCT/ISA/220

These notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

THIS PAGE BLANK (USPTO)

NOTES TO FORM PCT/ISA/220 (continued)

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; Claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 TO 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings which cannot be amended under Article 19(1).

The statement will be published with the international application and the amended claims.

The statement should be brief, it should not exceed 500 words if in English or if translated into English.

It should not be confounded with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It should not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

In what language?

The amendments must be made in the language in which the international application is published. The letter and any statement accompanying the amendments must be in the same language as the international application if that language is English or French; otherwise, it must be in English or French, at the choice of the applicant.

Consequence if a demand for international preliminary examination has already been filed?

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase?

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

THIS PAGE BLANK (USPTO)